Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Emergent Biosolutions (EBS) Com Stk USD0.001

Sell:$58.44 Buy:$58.49 Change: $1.12 (1.95%)
Market closed |  Prices as at close on 22 January 2020 | Switch to live prices |
Sell:$58.44
Buy:$58.49
Change: $1.12 (1.95%)
Market closed |  Prices as at close on 22 January 2020 | Switch to live prices |
Sell:$58.44
Buy:$58.49
Change: $1.12 (1.95%)
Market closed |  Prices as at close on 22 January 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).

Contact details

Address:
400 Professional Dr Ste 400
GAITHERSBURG
20879-3457
United States
Telephone:
+1 (240) 6313200
Website:
https://emergentbiosolutions.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EBS
ISIN:
US29089Q1058
Market cap:
$2.87 billion
Shares in issue:
51.62 million
Sector:
Biotechnology
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Fuad El-Hibri
    Executive Chairman of the Board
  • Robert Kramer
    President, Chief Executive Officer, Director
  • Richard Lindahl
    Chief Financial Officer, Executive Vice President, Treasurer
  • Katherine Strei
    Chief Human Resource Officer, Executive Vice President
  • Atul Saran
    Executive Vice President, Corporate Development, General Counsel and Corporate Secretary
  • Adam Havey
    Executive Vice President - Business Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.